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The aim of the current study was to investigate the oral antidiabetic activity of four structurally-related tri-
terpenic acids: ursolic (RE-01), oleanolic (RE-02), moronic (RE-03) and morolic (RE-04) acids. STZ-nicotin-
amide diabetic rats were treated with these triterpenes (50 mg/kg) and the antidiabetic effects in acute
experiment were determined. All compounds showed significant antidiabetic activity in comparison with
control group (p<0.05). The invitro inhibitoryactivityof compoundsagainstprotein tyrosinephosphatase1B
(PTPe1B) was also evaluated. At 50 mM, the enzymatic activity was almost completely inhibited. All
compoundswere dockedwith a crystal structure of PTPe1B. Docking results suggested the potential binding
of the triterpenicacids inabindingpocketnext to the catalytic site.Anextensivehydrogenbondnetworkwith
the carboxyl group and Van der Waals interactions stabilize the protein-ligand complexes.
 2011 Elsevier Masson SAS. All rights reserved.1. Introduction
Diabetesmellitus (DM) is a chronic disease that occurs when the
pancreas does not produce enough insulin or when the body
cannot effectively use it, resulting in hyperglycemia. Over time this
condition can cause serious damage to several body systems, in
particular the nerves and blood vessels. Type 2 DM, or non insulin
dependent diabetes, results from ineffective use of insulin as
consequence of excess body weight, physical inactivity, and genetic
susceptibility [1]. This disease has been becoming more common
because of a lifestyle and diet that promotes obesity; it’s particu-
larly prevalent in Hispanic and aging populations [2]. Treatment of
diabetes involves lowering blood glucose through different mech-
anisms, including insulin secretion, glucose absorption, and
metabolism [3]. Activation of PPAR-a and PPAR-g by rosiglitazonef J.J. Ramírez-Espinosa (Phar-
S. López (Phytochemical
.
.
son SAS. All rights reserved.[4] or inhibition of dipeptidyl peptidase-4 (DPP-4) by sitagliptin [5]
are novel approaches for the treatment of diabetes. Protein tyrosine
phosphatase 1B (PTPe1B) has recently shown an important influ-
ence over insulin sensitivity since it is implicated in modulating
insulin signal transduction becoming a key regulator of insulin-
receptor activity and downstream signaling pathways [6]. This is
related with a dephosphorylation of active insulin receptor (IR) [7].
Studies carried out with knock-out mice suggest that the lack of
PTPe1B enzyme would result in activated insulin receptors,
improved sensibility to insulin, and stimulated glucose uptake [8].
The study of medicinal plants has lead to the discovery of new
chemical structures for potential development as drugs that act
over new or known therapeutic targets. Thus, the Phoradendron
genus has been used in Mexico since ancient times for the treat-
ment of diabetes, hypertension, among other diseases [9]. Penta-
cyclic acid triterpenoids and other compounds isolated from
Phoradendron reichenbachianum, a parasitic herbal of Holm oaks,
have shown significant cytotoxic [10] and antiviral activities [11].
In an attempt to find novel antidiabetic drugs from medicinal
plants, herein we report in vivo, in silico, and in vitro studies of
a series of structurally-related pentacyclic acid triterpenoids (Fig. 1)
Fig. 1. Compounds evaluated.
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In addition, we report the results of in vitro enzymatic and in silico
experiments and discuss the possible mechanism of action of these
metabolites through the inhibition of PTPe1B.
2. Results and discussion
2.1. Chemistry
Ursolic (RE-01), oleanolic (RE-02), moronic (RE-03), andmorolic
(RE-04) acids were purified and characterized from acetone extract
of leaves and stems of Phoradendron reichenbachianum (AEPr) as
previously reported in Reference [10].
2.2. In vivo antidiabetic activity
Table 1 shows that i.g. administration of AEPr (100 mg/kg) and
RE-01, RE-02, RE-03 and RE-04 (50 mg/kg), induced, in general,
a significant decrease in plasma glucose concentration in diabetic
rats (p< 0.05) during acute time periods (7 h) as comparedwith the
control group (vehicle). All compounds showed significant antidia-
betic activity, inparticularRE-01 andRE-03 showed the best activity
as compared with the control group (p < 0.05). RE-01 and RE-03
produced a sustained decrease of blood glucose levels, close to 25%,
during all the experiment. The in vivo antidiabetic activity of RE-01
and RE-02 on streptozotocin-induced diabetic rats has beenTable 1
Percentage of variation of blood glucose concentration on streptozotocin-nicotinamide i
Test samples Dose (mg/Kg) Percentage of variation of glycemia
Zero hour First hour
Vehicle e 0  0.0 9.1  10.98
Glibenclamide 5 0  0.0 20.43  8.17*
AEPr 100 0  0.0 20.3  6.17*
RE-01 50 0  0.0 13.46  7.7*
RE-02 50 0  0.0 26.92  5.7*
RE-03 50 0  0.0 17.3  5.6*
RE-04 50 0  0.0 1.54  5.02*
* Values represent the mean  S.E.M. (n ¼ 6). p < 0.05 compared with control group. Thdescribed in References [12,13]. Also, RE-02 significantly (p < 0.05)
improved the glucose tolerance test at the 30 min period with
amaximal decline at 10mg/kg. Compared tovehicle-treated control,
RE-02 lowered the blood glucose levels by 30, 37, and 22%, respec-
tively, for the respective doses [14]. These previous reports are in
agreement with our results made on the non insulin-dependent
diabetes model. On the other hand, AEPr showed the same potency
as pure compounds, which suggests a possible additive action of
triterpenic acids contained there. Moreover, this is the first report
concerning the in vivo antidiabetic effect of AEPr, RE-03, and RE-04.
The in vitro enzymatic activity of RE-01 and RE-02 as antidia-
betic agents has been reported; both triterpenic acids induced
a significant PTPe1B [15,16] and 11b-HSD1 [17,18] enzymatic inhi-
bition. RE-02 enhanced the IRb tyrosine kinase activity and also
enhanced the effect of insulin on translocation of glucose trans-
porter 4 in 3T3eL1 adipocytes, a classical insulin-sensitive cell line
[19]. Therefore, we decided to determine the in vitro enzymatic
PTPe1B inhibition of RE-03 and RE-04 as structural related analogs
of RE-01 and RE-02. We also conducted automated docking studies
in order to propose a binding model with PTPe1B.
2.3. In vitro PTPe1B assay
To test the ability of each compound to inhibit PTPe1B, aliquots of
stock solutions (dissolved in DMSO to prepare 20 mM) were diluted
with the assay buffer, containing 2.5 mM p-nitrophenyl phosphatenduced diabetic rats treated with AEPr and pentacyclic acid triterpenoids.
 S.E.M. (mg/dL)
Third hour Fifth hour Seventh hour
1.71  5.11 0.51  5.11 5.67  6.09
36.34  7.55* 37.48  7.16* 43.64  9.9*
17.55  3.15* 26.42  10.87* 28.53  6.62*
24.45  10.9* 25.66  9.78* 38.01  5.0*
14.1  6.78* 23.2  9.9* 21.92  8.9*
26.3  5.9* 15.3  3.6* 29.2  4.0*
15.23  3.84* 8.77  4.86 39.18  2.72*
e negative value () indicates decrease in glycemia.
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Fig. 2. Assay of inhibition activity of ursolic (RE-01), oleanolic (RE-02), moronic (RE-
03), and morolic (RE-04) acids at 10 and 50 mM against PTP. All assays were performed
in 0.075 M b,b-dimethylglutarate buffer pH 7.0, containing 1 mM EDTA and 1 mM
dithiothreitol. The final concentration of the substrate (pNPP) in each assay was
2.5 mM. All experiments were performed in triplicate. The data reported represent the
mean  S.E.M.
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Fig. 4. Inhibition reversibility assay. Aliquots of PTP were incubated in the presence of
a fixed concentration of each compound for 1 h at 37 C (RE-01, 10 mM; RE-02, 25 mM;
RE-03, 35 mM; RE-04, 25 mM). Then, the enzyme was diluted 400-fold with the assay
solution to measure the residual activity (37 C, 10 mM pNPP). Control experiments
were carried out adding DMSO. All tests were performed in triplicate. The data
represent the mean  S.E.M.
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incubated at 37 C, and the reactions were initiated by adding an
appropriate enzyme aliquot. Fig. 2 shows the preliminary results. This
figure clearly shows that all compounds induced a significant enzyme
inhibition at both evaluated concentrations (10 and 50 mM), and the
inhibitioneffectsweremorepronouncedat thehighest concentration.
In order to determine the IC50 value of each compound, the
enzyme activity was measured at a fixed substrate concentration1E-3 0.01 0.1 1 10 100 1000
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Fig. 3. AeD: IC50 determination. The IC50 value for compounds RE-01 (A), RE-02 (B), RE-03
of the PTP against the inhibitor concentration. 15e18 different inhibitor concentrations were
mean  S.E.M.(corresponding to the Km) and varying inhibitor concentrations.
IC50 values were calculated by fitting experimental data in the
following equation, using a non-nonlinear fitting program (FigSys,
Biosoft, UK):
y ¼ MaxMin
1þ
 
x
IC50
!slope þMin1E-3 0.01 0.1 1 10 100 1000
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0.2
0.4
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1E-3 0.01 0.1 1 10 100 1000
0.0
0.2
0.4
0.6
0.8
1.0
1.2
v
i/v
o
[RE-04] µM
IC50 = 9.1 ± 0.5
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D
(C) and RE-04 (D) were determined by plotting the data relative to the residual activity
used for each inhibitor. All assays were performed in quadruplicate. Data represent the
Table 2
The IC50 values determined for different PTPases. For each inhibitor, between 15 and
18 different inhibitor concentrations were used. All tests were performed in tripli-
cate. The data represent the mean  S.E.M.
Compound REL01 REL02 REL03 REL04
Enzyme IC50 (mM)
PTP-1B 2.3  0.1 9.5  0.5 13.2  0.7 9.1  0.5
IF1 7.2  0.2 21.2  0.5 20.6  0.6 13.4  0.4
IF2 11.1  0.3 22.9  0.9 27.4  1.5 30.6  0.7
LTP1 20  0.7 44.8  1.7 51.2  0.9 52.0  0.3
LAR 3.8  0.1 11.8  1.0 45.6  3.0 35.9  8.3
J.J. Ramírez-Espinosa et al. / European Journal of Medicinal Chemistry 46 (2011) 2243e22512246where y ¼ vi/vo is the ratio between the measured activity in the
presence of the inhibitor (vi) and the activity of the control without
the inhibitor (vo). x is the inhibitor concentration.
All compounds induced a PTPe1B enzymatic inhibition in
a concentration-dependent manner (Fig. 3AeD). Moreover, RE-01
and RE-04 were the most potent inhibitors. RE-01 and RE-02
acids have been reported as inhibitors of PTPe1B with IC50 values
of 3.28 and 3.02 mM, respectively [15,16]. These results are in
agreement with our previous observations (Fig. 3AeD). Yet for RE-
03 and RE-04 acids, there are no reports concerning their PTPe1B
inhibitory properties. Also, the selectivity and type of inhibition
for these compounds have not been reported. Therefore, the
dilution method was used to determine the ability of each
compound to dissociate from PTPe1B after binding. The enzyme
was incubated for 1 h at 37 C in the presence of each inhibitor.Fig. 5. Double reciprocal plot of RE-01 (1/v versus 1/[S]) (A), the inhibitor concentrations we
Km (B) and Vmax (C) from the concentration of RE-01, the inhibitor concentrations were: 0,
graph, represent the means (A) or values (B and C)  S.E.M.Then aliquots of enzyme mixture was withdrawn and diluted with
the assay buffer to determine the residual activity. Fig. 4
summarizes the results indicating that the recovery of enzyme
activity is almost complete in all cases, with the exception of RE-
02, suggesting that most compounds behave as reversible
inhibitors.
We also determined the selectivity of each inhibitor towards
other none structurally related PTPases, such as the IF1, IF2 isoen-
zymes of human LMW-PTP, the yeast LMW-PTP (LTP1) and human
LAR. The selectivity was measured at the corresponding experi-
mental IC50 value of each compound. Results are summarized in
Table 2. All IC50 values for other PTPases were higher than the
corresponding IC50 value for PTPe1B. These results indicate that all
compounds are selective towards PTPe1B with respect to the other
PTPases tested.
To determine the inhibition mechanism of each compound, we
studied the effects of increasing inhibitors concentration on main
kinetics parameters, Km and Vmax (Figs. 5e8). We deduced from the
experimental results that the inhibition mechanism of compounds
RE-01, RE-02 and RE-03 (Figs. 5e7) can be referred to a linear
mixed-type inhibition model (Scheme 1), suggesting a possible
binding in a different cavity from the catalytic site. This was further
supported with molecular docking results discussed later. In
contrast, the inhibition mechanism of RE-04 (Fig. 8) can be referred
to a simple linear non-competitive inhibition model. The Ki values
for all compounds were calculated using the appropriate equations
and are presented in Table 3.re: 0 mMC; 2.5 mMB; 3.5 mM:; 4.5 mM7. Dependence of main kinetic parameters
2.5, 3.5 and 4.5 mM. All assays were performed by triplicate. The data reported in the
Fig. 6. Compound RE-02. Double reciprocal plot (1/v versus 1/[S]) (A), the inhibitor concentrations were: 0 mM-; 6.5 mMB; 10.5 mM:; 14.5 mM7. Dependence of main kinetic
parameters Km (B) and Vmax (C) from the concentration of RE-02, the concentrations of inhibitor used were: 0, 6.5, 10.5 and 14.5 mM. All assays were performed by triplicate. The
data reported in the graph, represent the means (A) or values (B and C)  S.E.M.
Fig. 7. Compound RE-03. Double reciprocal plot (1/v versus 1/[S]) (A), the concentrations of inhibitor used were: 0 mM -; 10 mM B; 15 mM :. Dependence of main kinetic
parameters Km (B) and Vmax (C) from the concentration of compound RE-03, the concentrations of inhibitor used were: 0, 10 and 15 mM. All assays were performed by triplicate. The
data reported in the graph, represent the means (A) or values (B and C)  S.E.M.
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Fig. 8. Double reciprocal plot of RE-04 (1/v versus 1/[S]) (A), the concentrations of inhibitor used were: 0 mM -; 7.5 mM B; 11 mM :; 15 mM 7. Dependence of main kinetic
parameters Km (B) and Vmax (C) from the concentration of compound RE-04, the concentrations of inhibitor used were: 0, 7.5, 11 and 15 mM. All assays were performed by triplicate.
The data reported in the graph, represent the means (A) or values (B and C)  S.E.M.
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In order to gain insight into the putative binding mode of RE-01,
RE-02, RE-03 and RE-04 with PTPe1B, these compounds were
docked with a crystallographic structure of human PTPe1B. The
crystallographic structure was obtained from the Protein Data Bank
(PDB), accession code 1C83 [20]. This is the first study describing
the docking of these triterpene derivatives with PTPe1B.E S
I
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K
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Scheme 1. The linear mixed-type inhibition of evaluated compounds. When the
parameter a ¼ 1, the model describes the classical non-competitive inhibition.
Table 3
Values of the inhibition constants (Ki) and docking scores. The data shown repre-
sents the mean Ki values  S.E.M.
Compound Ki (mM) a Inhibition type Docking score
(kcal/mol)
RE-01 3.4  0.7 3.4 Linear mixed type inhibition 7.15
RE-02 6.0  1.9 2.2 Linear mixed type inhibition 7.59
RE-03 8.0  2.0 2.3 Linear mixed type inhibition 7.50
RE-04 7.1  2.3 e Non-competitive inhibition 6.04In addition to the PTPe1B catalytic site, Puius et al. identified
a second aryl phosphate binding site in PTPe1B [21]. Fig. 9 shows
the catalytic binding site (site A) and the second binding site (site
B), as proposed by Puius et al. [21]. The most important residues of
site B are Arg24, Arg254, and Glu262. Other residues in this site are
Tyr46, Asp48, Val49, Ile219, and Met258 [21].
Before docking the triterpenic acids, the docking protocol was
validated by predicting the binding mode of the crystallographicFig. 9. Surface representation of the binding sites of PTPe1B. Catalytic binding site or
site A, is shown in yellow; binding site B, as reported by Yoram et al. [21] is in green.
A comparison between the binding position of the co-crystal ligand (red) and the
binding position predicted by AutoDock (blue) is also shown. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version
of this article).
Fig. 10. Docking of triterpenic acids with PTPe1B. A) Overlay of all triterpenic binding
modes. B) Surface representation of PTBe1B showing the binding mode of RE-01 into
the binding site B; residues forming hydrogen bonds with RE-01 are shown in red.
Residues making Van der Waals contacts with the ligand are shown in green.
Figure generated with PyMOL 1.0 [24]. C) Three-dimensional binding model of RE-01.
Hydrogen bonds are indicated with yellow dashes. D) Two-dimensional interaction
diagram of the predicted binding mode of RE-01. The binding site residues are rep-
resented as follows: polar residues in pink, acidic residues with a red contour ring,
basic residues with a blue contour ring. Green arrows indicate hydrogen bonding to
side chain atoms, respectively. The ligand proximity contour is depicted with a dotted
line. The ligand solvent exposure is represented with blue circles; larger and darker
circles on ligand atoms indicate more solvent exposure. The receptor solvent exposure
J.J. Ramírez-Espinosa et al. / European Journal of Medicinal Chemistry 46 (2011) 2243e2251 22496-(oxalyl-amino)-1H-indole-5-carboxilic acid, a competitive inhib-
itor of PTPe1B [20]. Fig. 9 shows a comparison between binding
mode of the crystallographic ligand and the binding mode predicted
by AutoDock. Fig. 9 clearly shows that AutoDock successfully pre-
dicted the binding mode of crystallographic ligand with a root-mean
square (RMS) deviation of 0.35 Å. Predicted binding energies for the
triterpenes are summarized in Table 3. The four compounds showed
comparable energies as calculated by AutoDock. Fig. 10 summarizes
the binding modes of the triterpenic acids predicted by AutoDock.
According to the dockingmodels, all four compoundswere predicted
to bind into the site B, thus sharing a very similar binding mode
(Fig. 10A and B). Interestingly, no binding poses were found by
AutoDock into the catalytic binding site. Fig. 10C depicts the opti-
mized binding mode of RE-01, the most active triterpene. In this
binding model, the carboxylic group of RE-01 at C28 forms an
extensive hydrogen bond network with Arg24, Arg254 and Gln262;
the surface of these residues is showed in red in Fig. 10B. Other
residues that form van der Waals contacts with the triterpene are
Tyr46, Asp48, Val49, Met258, and Gly259 (showed in green in
Fig. 10B). Fig. 10D shows the corresponding two-dimensional inter-
action diagram of the optimized binding model generated with the
program Molecular Operating Environment (MOE) [22].
3. Conclusions
We obtained four pentacyclic triterpenic acids from P. reich-
enbachianum with significant in vivo antidiabetic activity on non-
insulin dependent diabetic rat model. Moreover, the main mode of
action of triterpenic acids was produced by PTPe1B enzymatic
inhibition with potent, reversible, selective, and linear mixed-type
inhibition model. According to the docking results, the proposed
binding mode of the triterpene derivatives in a second binding site
(site B) of PTPe1B suggests a new strategy to obtain compounds
with higher affinity and specificity. Arg254 and Gln262 are
conserved among all PTPases, though other residues such as
Gln262, Met258 and Gly259 are less conserved. Finally, pentacyclic
triterpenic acids could be potential drugs for the treatment of type
2 diabetes as insulin sensitizer [23].
4. Experimental
4.1. Chemistry
Glibenclamide, nicotinamide, streptozotocin (STZ) and glucose
(GLU) were purchased from SigmaeAldrich Co. (St. Louis, MO, USA).
Pentobarbital (Anestesal) was obtained from Smith Kline Co.
(Mexico City, Mexico). Test evaluations for GLU were acquired from
Roche (ACCUTREND) (MexicoCity,Mexico).Ursolic (RE-01),Oleanolic
(RE-02), Moronic (RE-03) and Morolic (RE-04) acids were purified
and characterized from acetone extract of leaves and stems of P.
reichenbachianum (AEPr) as previously reported in Reference [10].
4.2. Biological assays
4.2.1. Expression and purification of recombinant PTPases
All experiments were performed using recombinant enzymes.
Human PTPe1B, the IF1 and IF2 isoenzymes of LMW-PTP, and the
yeast LMW-PTP (LTP1) were prepared and purified in our labora-
tory, whereas the recombinant catalytic domain of LAR (Leukocytedifferencesdin the presence and absence of the liganddare represented by the size
and intensity of the turquoise discs surrounding the residues; larger and darker discs
indicate residues highly exposed to solvent in the active site when the ligand is absent.
(For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article).
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enzymes were expressed in a bacterial line and purified by chro-
matography techniques. Briefly, the complete sequence of PTPe1B,
IF1, IF2, and LTP1 were cloned in the pGEXe2T bacterial expression
vector downstream the GST sequence. These vectors were used to
transform Escherichia coli TB1 strain. The recombinant fusion
proteins were purified from bacterial lysate using a single-step
affinity chromatography on glutathione-agarose. The solution
containing each purified fusion protein was treated with thrombin
for 3 h at 37 C. Then the active PTPases were purified fromGSTand
thrombin by gel filtration on a Superdex G75 column. The purity of
all enzymes was assessed by SDSePAGE.
4.2.2. Enzyme assays
All assays were carried out at 37 C. The substrate (pNPP) was
dissolved in 0.075 M of b,b-dimethylglutarate buffer pH 7.0, con-
taining 1 mM EDTA and 1 mM dithiothreitol. The final volume was
1 ml. The reactions were initiated by adding appropriate aliquots of
the enzyme, and stopped at final times with 4 ml of 1 M KOH. The
released p-nitrophenolate ion was determined by reading the
absorbance at 400 nm (e ¼ 18,000 M1 cm1). The main kinetic
parameters (Km and Vmax) were determined by measuring the
initial rates using eight different substrate concentrations in
the 0.5e40 mM range. Experimental data was analyzed using the
Michaelis equation and a nonlinear fitting program (FigSys).
4.2.3. Animals
MaleWistar rats weighing 200e250 g bodyweight were housed
at standard laboratory conditions and fed with a rodent pellet diet
and water ad libitum. They were maintained at room temperature
and a photoperiod of 12 h day/night cycle. Animals described as
fasted were deprived of food for 16 h but had free access to water.
All animal procedures were conducted in accordance with our
Federal Regulations for Animal Experimentation and Care
(SAGARPA, NOM-062-ZOO-1999, México), and approved by the
Institutional Animal Care and Use Committee based on US National
Institute for Health publication (No. 85e23, revised 1985).
4.2.4. Induction of diabetes
Streptozotocin (STZ) was dissolved in citrate buffer (pH 4.5) and
nicotinamide was dissolved in normal physiological saline solution.
T2DM was induced in overnight fasted rats by a single intraperi-
toneal injection of 65 mg/kg streptozotocin, 15 min after the i.p.
administration of 110 mg/kg of nicotinamide. Hyperglycemia was
confirmed by the elevated glucose concentration in plasma,
determined at 72 h by glucometer. The animals with blood glucose
concentration higher 250 mg/dl were used for the antidiabetic
screening.
4.2.5. In vivo antidiabetic assay (T2DM model)
The diabetic animals were divided into groups of six animals
each (n¼ 6). Rats of experimental groups were orally administered
a suspension of the compounds (prepared in 10% Tween 80)
(50 mg/kg body weight) and a similar suspension of dry acetone
extract (100 mg/kg body weight). Control group animals were also
fed with 10% Tween 80. Glibenclamide (5 mg/kg) was used as
hypoglycemic reference drug. Blood samples were collected from
the caudal vein at 0, 1, 3, 5 and 7 h after vehicle, sample and drug
administration. Blood glucose concentration was estimated by
enzymatic glucose oxidase method using a commercial glucometer
(Accutrend GCT, Roche). The percentage variation of glycemia for
each group was calculated in relation to initial (0 h) level,
according to: %Variation of glycemia¼ [(Gx G0)/G0] 100, where
G0 were initial glycemia values and Gx were the glycemia values
at þ1, þ3, þ5 and þ7 h respectively. All values were expressed asmean  S.E.M. Statistical significance was estimated by analysis of
variance (ANOVA), p < 0.05 and p < 0.01 implies significance.
4.3. Docking
Molecular Operating Environment (MOE) 2009.10 was used for
ligand and protein preparation, and molecular structure viewing.
The crystal structure was obtained from the PDB with the accession
code 1C83 [20]. Docking calculations were conducted with Auto-
Dock, version 4.0 [24] In short, AutoDock performs an automated
docking of the ligand with user-specified dihedral flexibility within
a protein rigid binding site. The program performs several runs in
each docking experiment. Each run provides one predicted binding
mode. All water molecules and 6-(oxalyl-amino)-1H-indole-5-car-
boxilic acid (crystallographic ligand) were removed from the
crystallographic structure and all hydrogen atoms were added. For
all ligands and protein, Gasteiger charges were assigned and non-
polar hydrogen atoms were merged. All torsions were allowed to
rotate during docking. The auxiliary program AutoGrid generated
the grid maps. Each grid was centered at the crystallographic
coordinates of the crystallographic compound. The grid dimensions
were 22.12  22.12  22.12 Å3 with points separated by 0.375 Å.
LennardeJones parameters 12e10 and 12e6, supplied with the
program, were used for modeling H-bonds and Van der Waals
interactions, respectively. The Lamarckian genetic algorithm was
applied for the search using default parameters. The number of
docking runs was 100. After docking, the 100 solutions were clus-
tered into groups with RMS lower than 1.0 Å. The clusters were
ranked by the lowest energy representative of each cluster. In order
to describe the ligand-binding pocket interactions, the top ranked
binding mode found by AutoDock in complex with the binding
pocket of PTPe1B was subject to full energyminimization using the
MMFF94 force field implemented in MOE until the gradient 0.05
was reached. PyMOL 1.0 [25] was used to generate the molecular
surface of docking models.
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